Phillip Weck, VP at Janssen to speak at 10th Cytokines Conference Jan 30-31 2012 in San Diego, CA

Nov. 22, 2011 - PRLog -- Phillip K. Weck, Vice President & Compound Development Team Leader at Janssen Pharmaceuticals R&D will give a featured presentation at the 10th Cytokines and Inflammation Conference to be held in San Diego, CA on January 30-31, 2012 by GTC.

Phillip Weck is responsible for Janssen’s SIMPONI® (golimumab).  He has over 30 years of experience in the pharmaceutical industry.  He has led laboratory research, clinical research, and drug development teams during his career.  Janssen R&D is part of the Pharmaceutical Companies of Johnson & Johnson.

Prior to his current position, he was Director, Drug Discovery Portfolio Management at GlaxoSmithKline where he supported a diverse therapeutic area that included oncology, microbial and musculoskeletal diseases.  He initially joined SmithKline Beecham in 1991 as Project Director for numerous projects in various stages of development.  He also worked in the Global Marketing Group where he was responsible for scientific and competitive differentiation of cardiovascular and pulmonary products.  Previously, he held positions at DuPont Merck as a Senior Project Manager, Burroughs Wellcome as a Senior Clinical Scientist, and Genentech as a Senior Research Scientist.

The10th Cytokines and Inflammation Conference will bring together a 50-50 mix of academic and industry authoritative experts from leading affiliations (such as Biogen Idec, Merck, ChemoCentryx, FDA, Abbott, Janssen, BMS, MedImmune, Centocor, NIH, Scripps, UCSD, Stanford, UCLA, Sanford-Burnham, LIAI, etc.) to cover many current and relevant aspects of basic, translational or full development cytokine biology and its applicability to human health.

This conference is also part of the Novel Immunotherapeutics Summit, which consists of this track and three other tracks:
1) 4th Immunotherapeutics and Immunomonitoring
2) Immunotherapeutics Partnering and Dealmaking
3) Allergy Drug Discovery and Development

For more information, please visit www.gtcbio.com

# # #

GTC organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.

GTC (Global Technology Community), LLC, is a privately held company founded in 2002.